PON1 Activity Biomarker for Heart Failure Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to assess the risk of major adverse cardiac events and heart failure progression in individuals, particularly in identifying those at high risk who require aggressive therapies or no interventions, due to challenges in diagnosing heart failure and predicting cardiovascular events.
Innovation Solution
Determining paraoxonase 1 (PON1) activity levels in serum or non-chelated plasma samples by measuring arylesterase, paraoxonase, lipolactonase, or lactonase activities using spectrophotometry, and comparing these levels to control values to identify individuals at risk of experiencing major adverse cardiac events, requiring revascularization, heart transplant, or unscheduled hospitalization for heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for heart failure, then diagnosis can be performed, but the ability to accurately predict major adverse cardiac events and identify high-risk individuals is insufficient
Solution Approach 1:
The patent introduces a new measurement parameter (PON1 activity level) to assess cardiovascular risk. By measuring paraoxonase 1 activity in serum or plasma samples and comparing it to control values, the method provides a quantitative biomarker that improves both measurement precision for risk prediction and reliability for diagnostic purposes. This parameter change enables identification of high-risk individuals independent of established cardiac risk factors.
2Reliability
If aggressive therapies are applied to all heart failure patients, then some high-risk patients may benefit, but healthcare costs increase and resources are wasted on low-risk patients
Solution Approach 1:
The patent enables differentiated treatment strategies by identifying specific subgroups of patients with low PON1 activity levels who are at high risk for major adverse cardiac events. Instead of uniform aggressive therapy for all patients, the method allows clinicians to target intensive interventions specifically to those who need them most, while avoiding unnecessary treatments in low-risk patients. This local quality approach optimizes both treatment effectiveness and resource allocation.
3Measurement precision
If comprehensive risk assessment methods are implemented, then patient outcomes may improve, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent extracts a single, specific biomarker (PON1 activity) from the complex array of potential cardiovascular risk factors. By focusing on this one extracted parameter that can be measured through standard spectrophotometric methods, the approach achieves comprehensive risk assessment accuracy without requiring complex multi-parameter diagnostic systems. This simplifies the diagnostic procedure while maintaining high risk assessment accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the accurate identification of individuals at risk of major adverse cardiac events and heart failure progression, enabling targeted therapies and resource allocation, independent of established cardiac risk factors, thereby improving patient outcomes and reducing healthcare costs.
Implementation Method 1
adding the substrate to the test subject's serum, non-chelated plasma, or both types of samples and determining the level of PON1 enzymatic activity in the samples, e.g., by measuring the absorbance of the substrate
Data Source
AI summary
Provided herein are methods for assessing the risk a test subject with heart failure has of experiencing a major adverse cardiac event, requiring revascularization, requiring a heart transplant, requiring unscheduled hospitalization for heart failure, progression of heart failure status, or any combination thereof. Also provided herein are methods for assessing the risk a test subject has of developing heart failure. The present methods comprise determining the levels of paraoxonase 1 activity in the serum, non-chelated plasma, or both in the test subject and comparing the level of PON1 activity in the test subject's sample with a control or baseline value based on levels of PON1 activity in serum, non-chelated plasma, or both samples from a population of control subjects. Also provided herein are kits useful in assessing such risks.